PLRZ News & Events

Polyrizon announced the signing of its first clinical trial agreement with a U.S.-based clinical research site specializing in allergy studies, marking a milestone toward the initiation of its clinical program for the Nasarix Allergy Blocker. The clinical site, located in Texas, will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the Nasarix Allergy Blocker in patients with seasonal allergic rhinitis. The clinical study will assess the performance of Polyrizon's investigational nasal spray designed to create a protective barrier against airborne allergens. The study is planned as a multi-center trial, with additional clinical sites expected to be added in the coming months. The trial will be conducted in accordance with international Good Clinical Practice standards and applicable regulatory requirements, supporting Polyrizon's broader regulatory strategy.

Polyrizon announced the submission of amended claims in its U.S. patent application for its proprietary intranasal drug delivery platform. The amended claims expand the scope of protection of the company's technology to include not only the core mucoadhesive composition, but also drug delivery systems and methods of use, which are designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. The expanded claims relate to compositions comprising sulfated polysaccharide polymers and additional polymeric components that form a uniform and continuous film upon contact with epithelial mucosa.

Polyrizon Ltd trading halted, volatility trading pause